ArteraAI Prostate Test Report

Active Surveillance Insights

For men with NCCN very low-, low-, and favorable intermediate-risk prostate cancer, comparing their risk of adverse pathology to that of other patients who were on active surveillance (AS) and underwent radical prostatectomy can help determine if AS is a suitable management option.

Additional Prognostic Endpoint

In addition to the 10-year risk of distant metastasis, 10-year risk of prostate cancer-specific mortality is also reported. This can help provide more information to support optimized decision-making.

Short-Term Androgen Deprivation Therapy (ST-ADT) Biomarker

For men with NCCN intermediate risk disease, an ST-ADT predictive biomarker result is provided. A “positive” result indicates the patient will likely benefit from ST-ADT added to radiation therapy. A “negative” result indicates the patient will likely not benefit from adding ST-ADT to radiation therapy. In a model validation study, 68% (575 patients) were classified as ST-ADT (–), indicating they could avoid treatment with ST-ADT. Only 32% (276 patients) were classified as ST-ADT (+) and predicted to derive benefit from adding ST-ADT to radiation therapy.

Comparison With National Comprehensive Cancer Network (NCCN) Risk Group

There is variability among patients within NCCN risk groups. A visualization is provided to show how the risk of metastasis, based on the ArteraAI risk score, compares to other patients with the same NCCN risk.

This graphic and text are dyanmic (same as current test report)

Data Supporting ST-ADT Interpretation

In a clinical study, intermediate-risk patients who were ST-ADT biomarker (+) had significantly reduced risk of metastasis at 15 years when adding ST-ADT to radiation therapy; patients who were ST-ADT biomarker (–) had little to no reduction in risk of metastasis when adding ST-ADT to radiation therapy. The accompanying Kaplan-Meier (K-M) curves show risk of distant metastasis over time. The K-M curve highlighted by the blue box represents the clinical study data supporting the clinical interpretation on page 2 of the report.